Compare VLY & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VLY | COGT |
|---|---|---|
| Founded | 1927 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 6.0B |
| IPO Year | N/A | 2018 |
| Metric | VLY | COGT |
|---|---|---|
| Price | $11.75 | $34.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 14 |
| Target Price | $13.92 | ★ $34.77 |
| AVG Volume (30 Days) | ★ 6.7M | 1.6M |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,871,000.00 |
| Revenue This Year | $23.47 | N/A |
| Revenue Next Year | $8.43 | $1,180.55 |
| P/E Ratio | $13.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.48 | $3.72 |
| 52 Week High | $13.87 | $43.73 |
| Indicator | VLY | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 35.33 | 34.08 |
| Support Level | $11.57 | $32.93 |
| Resistance Level | $12.31 | $41.02 |
| Average True Range (ATR) | 0.37 | 1.81 |
| MACD | -0.15 | -0.43 |
| Stochastic Oscillator | 7.73 | 6.42 |
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.